Skip to main content

Project #91:
Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19

While vaccines remain the best strategy to prevent COVID-19, recent evidence suggests monoclonal antibodies (nMABs) or antivirals could potentially benefit certain vulnerable populations before or after exposure to SARS-CoV-2, such as the unvaccinated or recently vaccinated high-risk patients.

With the recent roll out of nMABs and antivirals, there is an urgent need to for knowledge and understanding around the use of nMABs and antivirals in the treatment of patients with COVID-19, such as factors of relevance in determining nMAB and antiviral treatment and the impact of nMAB and antiviral treatment in real word settings.

This project will cover three main areas relating to the roll out of nMABs and antivirals for non-hospitalised patients with COVID-19; (1) eligibility and uptake, (2) effectiveness and (3) safety.

  • Study leads: Millie Green
  • Organisation: University of Oxford and London School of Hygiene and Tropical Medicine